Insights
Search Results
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
5.06.25
Wilson Sonsini Advises Weave Communications on its Acquisition of TrueLark
On May 6, 2025, Weave, a Lehi, UT-based provider of a customer experience and payments software platform, announced that it had entered into a definitive agreement to acquire TrueLark, a Palo Alto, CA-based provider of an AI-powered receptionist and front-desk automation platform. Wilson Sonsini Goodrich & Rosati advised Weave on the transaction.
Client Highlights
7.17.23
Wilson Sonsini Advises DTx Pharma on Acquisition by Novartis
On July 17, 2023, DTx Pharma, a preclinical-stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced that it has been acquired by Novartis. Wilson Sonsini Goodrich & Rosati advised DTx Pharma on the transaction.
Client Highlights
9.22.22
Wilson Sonsini Advises Aadi Bioscience, Inc. on $72.5 Million Private Placement Equity Financing
On September 22, 2022, Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, and pre-funded warrants to purchase up to an aggregate of 2,426,493 shares of common stock at a purchase price of $12.4999 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of common stock, to be immediately exercisable and remain exercisable until exercised in full. Aadi Bioscience anticipates the gross proceeds from the PIPE to be approximately $72.5 million, before deducting any offering related expenses. The financing is expected to close on September 26, 2022, subject to customary closing conditions.